JILL SLONAKER: Open Payments
NPI 1053918409 · WARSAW, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$757 in 47 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $372 · 2025 $757
Food & beverage: $757
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $166 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Novo Nordisk Inc | 5 | $86 |
| Lilly USA, LLC | 4 | $71 |
| AstraZeneca Pharmaceuticals LP | 4 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 1 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $29 |
Products named: VRAYLAR, REXULTI, JARDIANCE, MOUNJARO, CAPLYTA, Ozempic, FANAPT, Wegovy.
Industry payments across IN — which companies pay providers there.
